对于阻塞性多变性心肌病的Mavacamten:临床指导剂量定位以优化个人反应的合理性
Anjali T Owens1, Milind Desai2, Matthew T Wheeler3
1University of Pennsylvania Perelman School of Medicine Philadelphia PA USA.
Journal of the American Heart Association
|August 29, 2024
概括
马瓦卡门提供了一种新的治疗方法,用于阻塞性多变性心肌病. 以心声回声学为指导的剂量策略通过监测左心室外流通道梯度和射出分数来优化效益和安全性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阻塞性增高性心肌病 (oHCM) 是一种重要的心血管疾病.
- 马瓦卡门是一种新型心脏髓酶抑制剂,已批准用于症状NYHAII-III类oHCM.
- 个性化剂量对于优化治疗结果和安全至关重要.
研究的目的:
- 开发和验证基于心声回声的,临床指导的Mavacamten剂量定位策略.
- 为了优化患者在症状阻塞性多变性心肌病的好处.
- 为了最大限度地降低左心室射出小部分的风险.
主要方法:
- 使用基于证据的推理和临床参数进行剂量.
- 采用心声学来监测左心室 (LV) 外流通道梯度和LV喷射率.
- 包括临床试验数据,建模和模拟分析.
主要成果:
- 基于心声回声的策略成功地确定了个性化的mavacamten剂量,以改善结果.
- 在LV外流通道阻塞,功能能力和症状方面有明显的改善.
- 无论CYP2C19代谢器状态如何,都显示出有利的安全性.
结论:
- 一种以心声学为指导的剂量定位策略有效地优化了对oHCM的mavacamten治疗.
- 这种方法平衡了治疗疗效与减轻不良影响,如减少LV喷射分数.
- 该策略考虑了患者特定的因素,包括CYP2C19代谢和潜在的药物相互作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322